How the introduction of Claude AI across Bristol-Myers Squibb’s pipeline (BMY) changed the investment story

• Earlier this month, Bristol-Myers Squibb announced a broader partnership with Anthropic to bring Claude AI across research and clinical development, manufacturing, commercial, and enterprise functions to help accelerate drug development and operational workflows.
• The move signals a broader push for Bristol-Myers Squibb to integrate advanced data and AI tools across its development pipeline, with Tempus AI combining a separate AI-focused collaboration in clinical trial design.
• Here, we examine how Bristol-Myers Squibb’s efforts to embed Claude AI across its operations could reshape the company’s existing investment story.

Take advantage of the AI ​​infrastructure supercycle with our “handpicked selection” of the 46 best AI gold rushes that transform record demand into massive cash flows.

Bristol-Myers Squibb Investment Story Summary

To own Bristol-Myers Squibb, you need to believe that the company’s diversified pipeline and business footprint can offset the looming patent cliff and pricing pressures, despite consensus expectations for multi-year sales and profit declines. The new AI partnership with Anthropic, along with Tempus AI, could have some impact on the execution of key near-term catalysts: late-stage oncology and immunology ramp-ups. The biggest risk is how rapidly revenue from Eliquis, Opdivo, and other legacy products will decline.

The most relevant recent announcement here is BMS’ ASCO 2026 Oncology Data Slate, which includes Phase 3 results for CELMoD assets such as mesigdomide, as well as early results from next-generation CAR T and ADC programs. Coupled with AI-powered trial design, this series of oncology updates cuts straight to the heart of short-term catalyst issues. It’s about whether we can scale up new cancer drugs and labels fast enough to move the conversation beyond patent expiration.

But beneath this advancement in AI and oncology, investors should still be mindful of the potential for increased patent and pricing headwinds.

Read the full story on Bristol-Myers Squibb (it’s free!)

Bristol-Myers Squibb plans to have sales of $40.1 billion and profits of $8.6 billion by 2029. This would require annual sales to decline by 6.2% and profits to increase by about $1.3 billion from the current $7.3 billion.

Reveal how Bristol-Myers Squibb’s forecasts generate a fair value of $62.96, 6% above the current price.

explore other perspectives

Relative to the consensus view, the most optimistic analysts already expect revenues to increase towards about US$10.4 billion by 2029, so Claude and Tempus-led R&D improvements could either strengthen its bright margin story or reveal how sensitive those forecasts are to real-world test results and cost reductions.

Check out 12 other fair value estimates for Bristol-Myers Squibb – Why the stock is worth more than twice its current price!

reach one’s own conclusion

Don’t agree with the existing narrative? Following the herd rarely yields exceptional investment returns. Follow your intuition.

Are you considering other strategies?

At this time, our main inventory items are not attracting attention. Join early:

• Meet the 27 top quantum computing companies that are leading the revolution in next-generation technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are raw materials for most high-tech equipment, military and defense systems, and electric vehicles. Global competition continues to secure supplies of these critical minerals. Beat the pack to find the best 27 rare earth metal stocks of the very few that mine this important strategic resource.
• Find the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.